Ludwig Fischer von Weikersthal

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 3

Top Topics

Tyrosine Kinase

Metastatic Colorectal Cancer

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

International journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Arndt Stahler, Andreas Jay Kind, Christine Sers, Soulafa Mamlouk, Lothar Müller, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Ludwig Fischer von Weikersthal, Greta Sommerhäuser, Stefan Kasper, Beeke Hoppe, Annika Kurreck, Swantje Held, Volker Heinemann, David Horst, Armin Jarosch, Sebastian Stinzing, Tanja Trarbach, Dominik Paul Modest
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212). Clinical cancer research : an official journal of the American Association for Cancer Research 30 (7) (2024)
Arndt Stahler, Andreas Jay Kind, Christine Sers, Soulafa Mamlouk, Lothar Müller, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Ludwig Fischer von Weikersthal, Greta Sommerhäuser, Stefan Kasper, Beeke Hoppe, Annika Kurreck, Swantje Held, Volker Heinemann, David Horst, Armin Jarosch, Sebastian Stinzing, Tanja Trarbach, Dominik Paul Modest
Negative hyperselection of resistance mutations for panitumumab maintenance in RAS wild-type metastatic colorectal cancer (PanaMa phase II trial, AIO KRK 0212). Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Arndt Stahler, Volker Heinemann, Julian Walter Holch, Jobst Christian von Einem, Christoph Benedikt Westphalen, Kathrin Heinrich, Laura Schlieker, Ivan Jelas, Annabel Helga Sophie Alig, Laura Elisabeth Fischer, Lena Weiss, Dominik Paul Modest, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Markus Moehler, Florian Kaiser, Thomas Kirchner, Andreas Jung, Sebastian Stinzing
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3). International journal of cancer 149 (11) (2021)